Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPG7236 in Advanced Solid Tumors
NCT05142592Phase 2Completed
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of IPG7236 in solid tumor (6 cohorts), sponsored by Nanjing Immunophage Biotech Co., Ltd. Primary endpoints: Adverse Events up to 33 days, Maximum Tolerated Dose up to 33 days and 2 more. Started Nov 2021; status: completed.
02
Drugs
IPG7236
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05142592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142592.